790299-79-5 Masitinib AKSci A821
 
 
Loading Please Wait...
  A821    
Masitinib
, 98% (HPLC)
 
Masivet




IDENTITY
CAS Number:790299-79-5
MDL Number:MFCD09954132
MF:C28H30N6OS
MW:498.64
SPECIFICATIONS & PROPERTIES
Purity:98% (HPLC)
Spectra:NMR, LCMS, HPLC
Physical Form:White powder
Long-Term Storage:Store long-term at -20°C
UN #:Not hazmat

BIOLOGICAL INFO
Solubility:DMSO: 100mg/mL; H2O: <1mg/mL; EtOH: 4mg/mL
Application(s):Tyrosine kinases inhibitor for c-Kit, PDGFR, and FGFR.
Form:Free Base

REVIEW

 Masitinib is a targeted therapy that functions as a receptor tyrosine kinase inhibitor. This small molecule drug inhibits cell signaling by blocking the transfer of phosphate groups at the cell membrane. Masitinib has antitumor properties by selectively inhibiting KIT (also known as stem cell factor) which is a receptor known to be mutated or overactive in many mast cell tumors. Masitinib has antiangiogenic properties through its inhibition of platelet derived growth factor receptor. Interestingly, Masitinib also targets Lyn and Fak, key components of the transduction pathway leading to IgE induced degranulation. This effect expands the possible utility of Masitinib to include atopic disease, an area that has recently completed a clinically successful phase III study.

REFERENCES
[1]Lublin FD, Reingold SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis.
[2] Confavreux C, Vukusic S, Moreau T, Adeleine P: Relapses and progression of disability in multiple sclerosis.
[3] Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi MMX, De Sa J: Primary progressive multiple sclerosis.
[4] Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Casteran N, Borge L, Hajem B, Lermet A, Sippl W, et al.: Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


RELATED PRODUCTS
A821Masitinib
3415AHMasitinib mesylate

Current as of January 19, 2019


Download SDS

CATEGORIES

 APIs and Bioactives > Protein Kinase Inhibitors


PubChem